Funding Opportunity Announcement (FOA) Numbers: PA-19-077
Funding Opportunity Purpose
The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.
Research Objectives
This FOA invites the research community to submit applications focused on early discovery of malaria vaccine candidates, including those targeting one or more of the different life cycle stages (i.e., pre-erythrocytic stage, blood stage, and/or sexual stage) of the parasites that cause human malaria, especially Plasmodium falciparum and P. vivax. Research targeting vaccines that are broadly protective against multiple strains or species of the parasites and/or that provide long lasting efficacy, is also highly desirable. The goal is to identify and credential more protective antigens, and to generate new or improved immunogens and novel vaccine candidates for the global malaria vaccine development community to take further into development.
This FOA will support the identification, characterization, credentialing and validation of new protective antigens or vaccine candidates with appropriate assay systems or animal models. For purposes of this FOA, protective antigens or vaccine candidates should demonstrate appropriate functional characteristics, such as prevention of infection, amelioration of disease, interruption of transmission, or prevention of relapse, or other functional features when applicable.
Examples of research topics include, but are not limited to:
- Identification, characterization, credentialing and/or validation of novel protective antigens/peptides/epitopes;
- Discovery of new effective vaccines utilizing novel technology platforms, adjuvants, or vaccine strategies with either new or already known malaria antigens;
- Structure-based vaccine design and testing;
- Construction of novel attenuated whole organism-based antimalaria vaccines, especially late liver stage-arresting whole sporozoite vaccines, using genetic manipulation of Plasmodium parasites;
- Screening, testing, credentialing and/or validation of new vaccine candidates with novel assays or animal models.
Eligibility
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions.
Award Budget
Application budgets are not limited but need to reflect the actual needs of the proposed project.
Award Project Period
The maximum project period is 5 years.
Key Dates
Open Date (Earliest Submission Date): January 05, 2019
Letter of Intent Due Date(s): N/A
*Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Expiration Date: January 8, 2022
Deadline
Application Due Date(s)
The first standard application due date for this FOA is February 05, 2019.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
